A 24-Week, Blinded, Randomized, Placebo-Controlled Dose-Ranging Trial of Nasal PYY3-36 for Weight Loss in Healthy Obese Patients

Trial Profile

A 24-Week, Blinded, Randomized, Placebo-Controlled Dose-Ranging Trial of Nasal PYY3-36 for Weight Loss in Healthy Obese Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2008

At a glance

  • Drugs Peptide YY 3-36 (Primary) ; Sibutramine
  • Indications Obesity
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Aug 2008 Status changed from in progress to completed.
    • 01 Aug 2008 Primary endpoint not met, as reported in a MDRNA media release.
    • 08 Jan 2008 Status change from recruiting to in progress, from Nastech Pharmaceutical Company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top